Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: hoyasaxa who wrote (994)	4/19/2000 12:38:00 PM
From: Dauntless	Respond to of 52153

hoyasaxa - excuse me - you posted your own answer <<if close to FDA approval, why issue more shares at $12.5>> <<The company plans to use net proceeds to fund further clinical development of its product candidates, including Novastan, its anti-clotting drug, for research and development>> If you're talking about the PRICE, well I'm impressed that they got the offering done the week before last. The important thing here is that the Novastan approval is a virtual certainty - and the labeling will allow even broader use of the drug than the co. originally was trying for. Peter was right - there are not that many biotechs with approved drugs. This will be one of them in 30 - 60 days. Plus they've got a great pipeline behind it. Do yourself a favor & check out the whole story. Good luck